|Day Low/High||7.41 / 7.71|
|52 Wk Low/High||4.10 / 14.00|
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Insys Therapeutics, Inc.
It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.
In trading on Friday, shares of Insys Therapeutics Inc crossed below their 200 day moving average of $7.21, changing hands as low as $6.85 per share. Insys Therapeutics Inc shares are currently trading off about 5.9% on the day.
As cannabis becomes more and more legal, investors have started to wonder what that means for them.
Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?
Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.
The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.
Despite a growing trade war between the U.S, and China, drug officials in that country have pledged to try to stop the flow of fentanyl into the U.S.
SAN DIEGO, June 23, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Veevo Instruments Inc.
While cannabis remains illegal on a federal level, these seven names are making early inroads into the growing industry.
Investors in Insys Therapeutics Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new July 20th contracts and identified one put and one call contract of particular interest.
Investors in Insys Therapeutics Inc saw new options become available this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.
Foundation to become global leader in pharmaceutical cannabinoids and spray technology established in 2017 through new leadership and acceleration of product pipeline
Investors eyeing a purchase of Insys Therapeutics Inc stock, but tentative about paying the going market price of $7.57/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $5 strike, which has a bid at the time of this writing of 60 cents.
Pivotal study aims to evaluate safety and efficacy of company's novel CBD product candidate in rare type of pediatric epilepsy
Investors in Insys Therapeutics Inc saw new options begin trading this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new April 20th contracts and identified one put and one call contract of particular interest.
Marijuana stocks are still in their infancy, meaning there's a whole host of weed-adjacent stock moves waiting to be made. Here are the best bets.
A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.